Cargando…

Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children

Emergence of highly transmissible Omicron subvariants led to increased SARS-CoV-2 infection and disease in children. However, minimal knowledge exists regarding the neutralization capacity against circulating Omicron BA.4/BA.5, BA.2.75, BQ.1, BQ.1.1 and XBB.1 subvariants following SARS-CoV-2 vaccina...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bellusci, Lorenza, Grubbs, Gabrielle, Sait, Shaimaa, Yonker, Lael M., Randolph, Adrienne G., Novak, Tanya, Kobayashi, Takuma, Khurana, Surender
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10692185/ https://www.ncbi.nlm.nih.gov/pubmed/38040697 http://dx.doi.org/10.1038/s41467-023-43152-y

Ejemplares similares

Therapeutic potential of convalescent plasma and hyperimmune immunoglobulins against SARS-CoV-2 BQ.1, BQ.1.1, and XBB variants
por: Bellusci, Lorenza, et al.
Publicado: (2023)

Substantial Neutralization Escape by SARS-CoV-2 Omicron Variants BQ.1.1 and XBB.1
por: Miller, Jessica, et al.
Publicado: (2023)

Global threat from novel SARS-CoV-2 variants, BF.7, XBB.1.5, BQ.1, and BQ.1.1: variants of concern?
por: Varghese, Ryan, et al.
Publicado: (2023)

Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2
por: Zhu, Airu, et al.
Publicado: (2023)

Never ending story? Evolution of SARS-CoV-2 monitored through Gibbs energies of biosynthesis and antigen-receptor binding of Omicron BQ.1, BQ.1.1, XBB and XBB.1 variants
por: Popovic, Marko
Publicado: (2023)

Adaptability of single nucleotide polymorphism (SNP)-PCR for subtyping SARS-CoV-2 and a new SNP-PCR for XBB, XBB.1.5, and B.Q.1/B.Q.1.1
por: Ritchie, Gordon, et al.
Publicado: (2023)

Neutralization of BQ.1, BQ.1.1, and XBB with RBD-Dimer Vaccines
por: Li, Dedong, et al.
Publicado: (2023)

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants
por: Wang, Qian, et al.
Publicado: (2023)

An updated atlas of antibody evasion by SARS-CoV-2 Omicron sub-variants including BQ.1.1 and XBB
por: He, Qingwen, et al.
Publicado: (2023)

Antigenic mapping of emerging SARS-CoV-2 omicron variants BM.1.1.1, BQ.1.1, and XBB.1
por: Mykytyn, Anna Z, et al.
Publicado: (2023)

Striking antibody evasion of SARS-CoV-2 Omicron sub-lineages BQ.1.1, XBB.1 and CH.1.1
por: Ju, Bin, et al.
Publicado: (2023)

Poor neutralizing antibody responses against SARS‐CoV‐2 Omicron BQ.1.1 and XBB in Norway in October 2022
por: Vikse, Elisabeth Lea, et al.
Publicado: (2023)

SARS-CoV-2 Variants BQ.1 and XBB.1.5 in Wastewater of Aircraft Flying from China to Denmark, 2023
por: Qvesel, Amanda Gammelby, et al.
Publicado: (2023)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

The rapid rise of SARS‐CoV‐2 Omicron subvariants with immune evasion properties: XBB.1.5 and BQ.1.1 subvariants
por: Ao, Danyi, et al.
Publicado: (2023)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Rise of the BQ.1.1.37 SARS-CoV-2 Sublineage, Italy
por: Focosi, Daniele, et al.
Publicado: (2023)

Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution
por: Taylor, Ashley L., et al.
Publicado: (2023)

Broad protective RBD heterotrimer vaccines neutralize SARS-CoV-2 including Omicron sub-variants XBB/BQ.1.1/BF.7
por: Zhang, Yanfang, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 BQ.1.1, CH.1.1, and XBB.1.5 by breakthrough infection sera from previous and recent waves in China
por: Wang, Xun, et al.
Publicado: (2023)

Rapid engineering of SARS-CoV-2 therapeutic antibodies to increase breadth of neutralization including BQ.1.1, CA.3.1, CH.1.1, XBB.1.16, and XBB.1.5
por: Entzminger, Kevin C, et al.
Publicado: (2023)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

A bivalent ChAd nasal vaccine protects against SARS-CoV-2 BQ.1.1 and XBB.1.5 infection and disease in mice and hamsters
por: Ying, Baoling, et al.
Publicado: (2023)

XAV-19, un anti-variant de Sars-CoV-2, BQ.1.1 compris
por: Manus, Jean-Marie
Publicado: (2023)

Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
por: Ito, Jumpei, et al.
Publicado: (2023)

Further quantitative in silico analysis of SARS-CoV-2 S-RBD Omicron BA.4, BA.5, BA.2.75, BQ.1, and BQ.1.1 transmissibility
por: Hanai, Toshihiko
Publicado: (2023)

Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2023)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Distinct Neutralizing Antibody Escape of SARS-CoV-2 Omicron Subvariants BQ.1, BQ.1.1, BA.4.6, BF.7 and BA.2.75.2
por: Qu, Panke, et al.
Publicado: (2022)

Consensus insertion/deletions and amino acid variations of all coding and noncoding regions of the SARS-CoV-2 Omicron clades, including the XBB and BQ.1 lineages
por: Suharsono, Hamong, et al.
Publicado: (2023)

Replicative capacity of SARS-CoV-2 omicron variants BA.5 and BQ.1.1 at elevated temperatures
por: Muramoto, Yukiko, et al.
Publicado: (2023)

COVID-19 Bivalent Booster in Pregnancy: Maternal and Neonatal Antibody Response to Omicron BA.5, BQ.1, BF.7 and XBB.1.5 SARS-CoV-2
por: Chen, Wei-Chun, et al.
Publicado: (2023)

Fourth mRNA vaccination increases cross-neutralizing antibody titers against SARS-CoV-2 variants, including BQ.1.1 and XBB, in a very elderly population
por: Sutandhio, Silvia, et al.
Publicado: (2023)

Humoral Responses against BQ.1.1 Elicited after Breakthrough Infection and SARS-CoV-2 mRNA Vaccination
por: Tauzin, Alexandra, et al.
Publicado: (2023)

Antiviral activities of sotrovimab against BQ.1.1 and XBB.1.5 in sera of treated patients
por: Bruel, Timothée, et al.
Publicado: (2023)

Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model
por: Driouich, Jean-Sélim, et al.
Publicado: (2023)

BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancer
por: Ehmsen, Sidse, et al.
Publicado: (2023)

Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection
por: Jiang, Xiao-Lin, et al.
Publicado: (2023)

Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
por: Hérate, Cécile, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_3aqi7qdr7crsqc7svcsuoruqke